GSK stock news · GlaxoSmithKline
Get alerts for GSK
Follow GlaxoSmithKline (GSK) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for GSKIndia has set limits on how much profit can be made from cancer drugs.
Good for GSKIndia placed price limits on 137 cancer drugs, but GSK's Jemperli kept its manufacturer price unchanged. This modestly supports GSK by avoiding a reported price cut.
Analyst Rating Changes for GSK plc
NeutralJefferies cut GSK's rating and target, but AlphaValue/Baader Europe upgraded it to Buy. The opposing views report no business change, so GSK's outlook is unchanged.
Jefferies changed GSK's rating from Buy to Hold and cut its price target.
Bad for GSKGSK received lower analyst ratings and price estimates, and analysts cited slow progress in its drug pipeline. This points to weaker confidence in its outlook.
GSK got the green light from the FDA for its new drug to treat chronic hepatitis B.
Good for GSKGSK won FDA approval for Hibsago, a hepatitis B treatment that helped some trial patients stay free of detectable virus after stopping therapy. The approval favors GSK despite serious safety warnings.
The FDA has given the green light to GSK's Hibsago (bepirovirsen) to treat chronic hepatitis B.
Good for GSKGSK received FDA approval for Hibsago, a treatment for a defined group of adults with chronic hepatitis B. The new approved medicine gives GSK a chance to add sales.
GSK got the green light from the FDA for Hibsago, a new medicine for chronic hepatitis B.
Good for GSKGSK won US approval for Hibsago to treat chronic hepatitis B, allowing it to offer the treatment to patients in the United States. This expands its treatment options.
The FDA has approved a GSK medicine that might change how doctors treat some rectal cancers.
Good for GSKGSK received FDA approval for Jemperli in a small group of rectal cancer patients. The new use is favorable for GSK, despite limited reach and differing response results.
Bill Cassidy claims that Trump's decision to reduce childhood vaccine recommendations to 11 is misguided.
Bad for GSKGSK's Priorix vaccine could be affected by the reduction in recommended vaccines, potentially impacting sales.
An executive order concerning autism and vaccines is being contemplated by the Trump administration shortly after RFK Jr. suggested 'specific interventions.
NeutralThe Trump administration is considering an executive order regarding vaccines and autism, which could lead to significant changes in vaccine policy. This uncertainty may affect companies like GSK that are involved in vaccine production, as the administration's stance could influence public perception and regulatory frameworks.